ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) (HIFU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02011919
Recruitment Status : Completed
First Posted : December 13, 2013
Last Update Posted : May 30, 2018
Sponsor:
Information provided by (Responsible Party):
Theraclion

Brief Summary:

This is a monocenter, open-label, uncontrolled study in accordance with §23b MPG to evaluate the efficacy of the HIFU-treatment of fibroadenoma using the TH-One device

Objectives Primary objective: To evaluate the efficacy of HIFU in the treatment of the breast fibroadenoma using the TH-One device Secondary objective: To evaluate the tolerability of the HIFU using the TH-One device


Condition or disease Intervention/treatment Phase
Breast Fibroadenoma Device: Echopulse Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Study Start Date : December 2013
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Arm Intervention/treatment
Echopulse
Echopulse HIFU
Device: Echopulse
HIFU Under ultrasound guidance




Primary Outcome Measures :
  1. FA volume changes from baseline [ Time Frame: Every year during 5 years ]

Secondary Outcome Measures :
  1. Palpability [ Time Frame: Every year during 5 years ]
    Lack of palpable lesion

  2. Pain assessment [ Time Frame: Every year during 5 years ]
    Pain free if pain at baseline (pain related to the FA)

  3. Cosmetic result [ Time Frame: Every year during 5 years ]
    Cosmetic result (as judged by investigator)

  4. Gland vascularisation [ Time Frame: Every year during 5 years ]
    Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12, year 2, 3, 4 and 5 after the HIFU session

  5. Histological outcome [ Time Frame: Every year during 5 years ]
    Histological outcome through core needle biopsy after 12 month

  6. Energy settings [ Time Frame: Every year during 5 years ]
    Energy setting to obtain reduction in volume or total regression of the FA at 12 months, 2, 3, 4 and 5 years follow-up

  7. Breast immobilization [ Time Frame: Every year during 5 years ]
    Quality and ease of use of breast immobilization

  8. Duration of the treatment session [ Time Frame: Every year during 5 years ]
    Duration of the treatment session (min)

  9. Ease of implementation of treatment [ Time Frame: Every year during 5 years ]
    Ease of implementation of treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients 18 years or older with at least one diagnosed breast fibroadenoma.
  • Diagnosis of fibroadenoma must be based on:

    • clinical examination,
    • women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram,
    • histological confirmation of fibroadenoma of the breast.
  • Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm.
  • Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment.
  • Patient must be able to understand the nature and the extent of the study and the procédures required and be willing and able to complete the screening and study procedures.
  • Patient must give written informed consent (personally signed and dated) before completing any study-related procedure.

Exclusion Criteria:

  • Patient who is pregnant or breast-feeding.
  • Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion.
  • Patient with implant on the treated breast.
  • Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU.
  • Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit.
  • Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02011919


Locations
Germany
Tubingen University Hospital
Tubingen, Germany
Sponsors and Collaborators
Theraclion

Responsible Party: Theraclion
ClinicalTrials.gov Identifier: NCT02011919     History of Changes
Other Study ID Numbers: HIFU / TU / FA
First Posted: December 13, 2013    Key Record Dates
Last Update Posted: May 30, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Fibroadenoma
Neoplasms, Fibroepithelial
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial